PlainPharmaWatch

CMS Open Payments · Program Year 2024

Meitheal Pharmaceuticals, Inc.

Meitheal Pharmaceuticals, Inc. reported $3,347.67 across General Payments, Research, and Ownership to 9 physicians and teaching hospitals across 9 transactions.

See the rankings → How this is sourced
$3.3K
All-tracks total
9
Transactions
9
Recipients
#1757
of 1,925 companies

Meitheal Pharmaceuticals, Inc. reported $3,347.67 across all CMS Open Payments tracks (General + Research + Ownership) to 9 physicians and teaching hospitals in Program Year 2024 - ranking #1757 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $3,347.67, averaging $371.96 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer meitheal-pharmaceuticals-inc Meitheal Pharmaceuticals, Inc.

$3.3K · #1757/1,925 · 0.0% industry · PY2024

  • TOT $3.3K
  • RANK #1757
  • SHARE 0.0%
  • TXN 9
  • RCP 9
  • CAT 2
  • GEN $3.3K
  • TOP1 24.8%
  • PY 2024

Volume peers

Nearest volume peer: BonaliveInc ($3.3K)

Xiros Inc$3.4KMeitheal Pharmaceuticals, In…$3.3KBonaliveInc$3.3KNorthern X-Ray Company$3.3KPillar Biosciences, Inc$3.3K
All-tracks payment totals near Meitheal Pharmaceuticals, Inc. (CMS Open Payments PY2024)

Meitheal Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Meitheal Pharmaceuticals, Inc.

In Program Year 2024, Meitheal Pharmaceuticals, Inc. reported $3,347.67 in payments to 9 physicians and teaching hospitals across 9 individual transactions, an average of $371.96 per transaction and $371.96 per recipient. That total places Meitheal Pharmaceuticals, Inc. at rank #1757 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

4 transactions worth $3.0K make "Honoraria" the top general-payment category in the 2-category breakdown below, 89.6% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 2 types of general payments, Meitheal Pharmaceuticals, Inc.'s largest category was "Honoraria" at $3.0K - 89.6% of General Payments.

How Meitheal Pharmaceuticals, Inc. divides its payments

How the reported total splits across payment categories

1. Honoraria$3.0K2. Food and Beverage$347.67
Payment Type Amount Transactions
Honoraria $3.0K 4
Food and Beverage $347.67 5

Recipient Concentration in General Payments

The five largest recipient relationships account for $3,347.67 (100.0%) of $3,347.67 in this company's General Payments records across 5 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Meitheal Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Jose Vazquez$830.19Andrew Shorr$830.19Yoav Golan$830.19Cornelius Clancy$830.19Allison Rodgers$26.91
  1. 1

    Jose Vazquez

    $830.19 across 2 reported transactions

  2. 2

    Andrew Shorr

    $830.19 across 2 reported transactions

  3. 3

    Yoav Golan

    $830.19 across 2 reported transactions

  4. 4

    Cornelius Clancy

    $830.19 across 2 reported transactions

  5. 5

    Allison Rodgers

    $26.91 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Meitheal Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Meitheal Pharmaceuticals, Inc..

Naviswiss, Inc.

HHI 2455

ParaPRO, LLC

HHI 2454

The Binding Site Inc.

HHI 2452

Shalby Advanced Technologies, Inc.

HHI 2474

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Meitheal Pharmaceuticals, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Meitheal Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.